Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026

globenewswire.com
IVA The article is a regulatory filing regarding voting rights and share capital. It mentions Inventiva's listing on Nasdaq but does not provide any performance or outlook information.

Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026 Article R. 22-10-23 of the French Commercial Code

Market : Euronext Paris

ISIN code / Mnemo: FR0013233012 / IVA

Web site: www.inventivapharma.com

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). https://www.inventivapharma.com

Contacts

Attachment